Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2019 | Pages:
80 | Publisher: Grand View Research
Industry: Pharmaceutical | Report Format: Electronic (PDF)
The U.S. prostate cancer nuclear medicine diagnostics market size is expected to reach over USD 389.1 million by 2026 according to a new report by Grand View Research, Inc. It is anticipated to register a CAGR of 10.7% during the forecast period. According to the American Cancer Society (ACS), in 2019, 174,650 new cases and 31,620 deaths caused by caused by prostate cancer are expected to be recorded in U.S. Such high prevalence of the disease is expected to drive the market growth. Development of novel radiopharmaceuticals to improve the detection of the target disease is anticipated to accelerate the market growth. For instance, new imaging agents targeting Prostate-specific Membrane Antigen (PSMA) are being developed using 68Ga and 18F radioisotopes. In addition, numerous studies are being performed by researchers to develop new diagnostic agents for Positron Emission Tomography (PET) with higher efficiency as compared to the existing agents. For instance, 89Zr-huJ591 is an imaging agent used with PET for the detection of prostate cancer. This agent is in phase I/II of clinical trials, and is likely to get launched over the forecast period. Growing demand for accurate diagnostic methods is estimated to fuel growth of the U.S. prostate cancer nuclear medicine diagnostics market. PET is commonly integrated with MRI and CT scan to enhance accuracy of diagnosis in malignancies. Therefore, researchers are conducting studies on PET/MRI to improve patient outcomes. For instance, in December 2018, a study was published in The Journal of Nuclear Medicinestating that 68Ga-PSMA-11 PET/MRI can be advantageous in detecting the target tumor. Various non-profit organizations fund research studies to help introduce new imaging agents for the diagnosis of tumors. The Prostate Cancer Foundation is one of the major organizations that has been funding different studies for the development of PSMA-PET imaging for over 20 years. Presence of such funding organizations and programs is expected to boost the market growth during the forecast period. Key market players have undertaken strategic initiatives to strengthen their market presence. For instance, in February 2018, Axumin (fluciclovine F 18) injection was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for Prostate Cancer. The updated guidelines used by clinicians and healthcare providers stated that fluciclovine F 18 for PET/MRI or PET/CT is considered in the clinical workup of patients with recurrent or advanced prostate cancer. Further key findings from the study suggest: • In 2018, PET led the U.S. prostate cancer nuclear medicine diagnostics market owing to increased sensitivity and quantification of biochemical and physiological processes at a molecular level • In the product segment, GA 68 PSMA is anticipated to register the fastest CAGR over the forecast period due to high detection rate and accuracy to detect the target tumor • Fluorine-18 led the PET products in 2018 owing to higher diagnostic performance and high-quality images, with a shorter acquisition time • Key market players include PETNET Solutions, Inc.; Blue Earth Diagnostics, Inc.; Cardinal Health; Jubilant Pharma Ltd. (Triad Isotopes, Inc.); Lantheus Medical Imaging; NCM-USA LLC; Telix Pharmaceuticals, Inc.; Progenics Pharmaceuticals, Inc.; ImaginAb, Inc.; Theragnostics Ltd.; and others
Table of Contents
Chapter 1 Methodology and Scope
1.1 Research Methodology
1.2 Research Scope and Assumptions
1.3 Limitation
1.4 List of Abbreviations
Chapter 2 Executive Summary
2.1 Market Summary
Chapter 3 Market Variables, Trends & Scope
3.1 Market Segmentation
Chapter 4 Market Definitions
Chapter 5 Industry Outlook
5.1 Market Lineage Outlook
5.1.1 Parent Market Outlook
5.2 Penetration and Growth Prospect Mapping
5.3 Market variable Analysis
5.3.1 Rising Incidence Of Prostate Cancer
5.3.2 Development Of Novel Radiopharmaceuticals
5.3.3 Growing Demand For Accurate Diagnostic Methods
5.3.4 Presence Of Reimbursement Policies And Funding Programs
5.4 Market Restraint Analysis
5.4.1 Stringent Regulations Pertaining To Production, Storage, & Usage
5.4.2 High Costs Associated With Diagnostic Procedures
5.5 SWOT Analysis; By factor (Political & legal, economic and technological)
5.6 Porter's five forces analysis
5.7 Regulatory Scenario
5.7.1 U.S.
Chapter 6 Competitive Analysis
6.1 Recent Developments & Impact Analysis, By Key Market Participants
6.2 Vendor Landscape
6.2.1 Key Market Share Analysis, 2018
6.3 Private Companies
6.3.1 Regional Network Map
Chapter 7 Type Business Analysis
7.1 U.S. Prostate Cancer Nuclear Medicine Diagnostics Market: Type Movement Analysis
7.1.1 SPECT
7.1.1.1 SPECT market, 2014 - 2026 (USD Million)
7.1.2 PET
7.1.2.1 PET market, 2014 - 2026 (USD Million)
Chapter 8 Product Mode Business Analysis
8.1 U.S. Prostate Cancer PET Nuclear Medicine Diagnostics Market: Product Movement Analysis
8.1.1 F18
8.1.1.1 F18 market, 2014 - 2026 (USD Million)
8.1.2 C11
8.1.2.1 C11 market, 2014 - 2026 (USD Million)
8.1.3 GA 68 PSMA
8.1.3.1 Ga 68 PSMA market, 2014 - 2026 (USD Million)
Chapter 9 Company Profile
9.1 BLUE EARTH DIAGNOSTICS LIMITED.
9.1.1 Company overview
9.1.2 Product benchmarking
9.1.3 Strategic initiatives
9.2 PETNET SOLUTIONS INC.
9.2.1 Company overview
9.2.2 Financial performance
9.2.3 Product benchmarking
9.2.4 Strategic initiatives
9.3 CARDINAL HEALTH
9.3.1 Company overview
9.3.2 Financial performance
9.3.3 Product benchmarking
9.4 CURIUM PHARMA
9.4.1 Company overview
9.4.1.1 Product benchmarking
9.4.1.2 Strategic initiatives
9.4.2 LANTHEUS MEDICAL IMAGING
9.4.2.1 Company overview
9.4.2.2 Financial overview
9.4.2.3 Product benchmarking
9.4.3 ADVANCED ACCELERATOR APPLICATIONS
9.4.3.1 Company overview
9.4.3.2 Product benchmarking
9.4.3.3 Strategic initiatives
9.5 JUBILANT PHARMA. LLC (TRIAD ISOTOPES, INC.)
9.5.1 Company overview
9.5.2 Financial performance
9.5.3 Product benchmarking
9.5.4 Strategic initiatives
9.6 NCM-USA LLC
9.6.1 Company overview
9.6.2 Product benchmarking
9.6.3 PROGENICS PHARMACEUTICALS, INC.
9.6.3.1 Company overview
9.6.3.2 Financial performance
9.6.3.3 Product benchmarking
9.6.3.4 Strategic initiatives
9.7 TELIX PHARMACEUTICALS LIMITED
9.7.1 Company overview
9.7.2 Financial performance
9.7.3 Product benchmarking
9.7.4 Strategic initiatives
9.8 IMAGINAB, INC.
9.8.1 Company overview
9.8.2 Product benchmarking
9.8.3 Strategic initiatives
9.9 THERAGNOSTICS
9.9.1 Company overview
9.9.2 Product benchmarking
9.9.3 Strategic initiatives
9.10 NOVARTIS AG
9.10.1 Company overview
9.10.2 Product benchmarking
9.10.3 Strategic initiatives
9.11 LIFE MOLECULAR IMAGING (ALLIANCE MEDICAL MOLECULAR IMAGING)
9.11.1 Company overview
9.11.2 Product benchmarking
9.11.3 Strategic initiatives
9.12 ABX ADVANCED BIOCHEMICAL COMPOUNDS GMBH
9.12.1 Company overview
9.12.2 Product benchmarking
9.13 ROTOP PHARMAKA GMBH
9.13.1 Company overview
9.13.2 Product benchmarking
9.13.3 Strategic initiatives
List of Tables Table 1 List of Abbreviation Table 2 List of key emerging companies /technology disruptors/innovators Table 3 F-18 pipeline radiopharmaceuticals Table 4 Ga-68 pipeline radiopharmaceuticals Table 5 U.S.Prostate Cancer Nuclear Medicine Diagnostics Market, By Type, 2014 - 2026 (USD Million) Table 6 U.S.Prostate Cancer PET Nuclear Medicine Diagnostics Market, By Product, 2014 - 2026 (USD Million)
List of Figures Fig. 1 U.S. prostate cancer nuclear medicine diagnostics market snapshot Fig. 2 U.S. prostate cancer nuclear medicine diagnostics market segmentation Fig. 3 Parent market outlook Fig. 4 Penetration and growth prospect mapping Fig. 5 U.S. prostate cancer nuclear medicine diagnostics market driver impact Fig. 6 U.S. prostate cancer (percent of cases by stages ) Fig. 7 U.S. prostate cancer nuclear medicine diagnostics market restraint impact Fig. 8 SWOT analysis, by factor (political & legal economic and technological) Fig. 9 Porter's five forces analysis Fig. 10 Company market position analysis Fig. 11 Regional Network Map Fig. 12 U.S. Prostate Cancer Nuclear Medicine Diagnostics Market: Type outlook and key takeaways Fig. 13 U.S. Prostate Cancer Nuclear Medicine Diagnostics Market: Type movement analysis Fig. 14 SPECT market, 2014 - 2026 (USD Million) Fig. 15 PET market, 2014 - 2026 (USD Million) Fig. 16 U.S. Prostate Cancer PET Nuclear Medicine Diagnostics Market: product outlook and key takeaways Fig. 17 U.S. Prostate Cancer PET Nuclear Medicine Diagnostics Market: Product Movement Analysis Fig. 18 F18 market, 2014 - 2026 (USD Million) Fig. 19 C11 market, 2014 - 2026 (USD Million) Fig. 20 Ga 68 PSMA market, 2014 - 2026 (USD Million) Fig. 21 Company Profile
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
